Clinical Trial Detail

NCT ID NCT01682083
Title Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST